|Dermatomyositis masquerading as pulmonary embolism.|
|Jump to Full Text|
|PMID: 20156749 Owner: NLM Status: MEDLINE|
|A 61-year-old Caucasian was admitted to Department of Chest Diseases and Tuberculosis, Medical University of Bialystok, Poland for progressive muscle weakness and weight loss. Eighteen months prior to admission, the patient had been diagnosed with pulmonary embolism. At that point he was started on Enoxaparin QD. Past medical history was unremarkable. In the interim, the patient developed fever, myalgia and progressive dyspnea. Physical examination on admission revealed a rash on his upper torso and back, and the extensor surfaces of all four extremities. Laboratory values included CPK 8229, MB fraction 219, LDH 981. Chest X-ray and CT scan revealed bilateral patchy consolidations and ground-glass opacities. EMG was consistent with myositis. The patient was started on solumedrol 40 mg i.v., b.i.d., and then switched to prednisone 40 mg b.i.d. His symptoms and muscle strength improved remarkably. The patient was discharged with prednisone with an outpatient follow up.|
|R M Mroz; M Korniluk; E Chyczewska|
Related Documents :
|15042689 - Strongyloidiasis in patients at a comprehensive cancer center in the united states.
3120379 - Distant procurement of organs for clinical heart-lung transplantation using a single fl...
2788909 - Comparison of younger and elderly patients with pulmonary tuberculosis.
19446279 - Role of endothelin-1 in acute lung injury.
17180299 - Juvenile onset systemic sclerosis: a single center experience of 23 cases from asia.
12683709 - Pulmonary functions in patients with epidemic dropsy.
10225239 - Is streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? a micro...
17600479 - Radiosynoviorthesis of knees by means of 166ho-holmium-boro-macroaggregates.
9778279 - Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year exper...
|Type: Case Reports; Journal Article|
|Title: European journal of medical research Volume: 14 Suppl 4 ISSN: 0949-2321 ISO Abbreviation: Eur. J. Med. Res. Publication Date: 2009 Dec|
|Created Date: 2010-02-16 Completed Date: 2010-08-10 Revised Date: 2013-03-27|
Medline Journal Info:
|Nlm Unique ID: 9517857 Medline TA: Eur J Med Res Country: Germany|
|Languages: eng Pagination: 162-4 Citation Subset: IM|
|Department of Lung Diseases and Tuberculosis,Medical University of Bialystok, Bialystok, Poland. Robmroz@wp.pl|
|APA/MLA Format Download EndNote Download BibTex|
Pulmonary Embolism / diagnosis*
Journal ID (nlm-ta): Eur J Med Res
Journal ID (iso-abbrev): Eur. J. Med. Res
Publisher: BioMed Central
Copyright ©2009 I. Holzapfel Publishers
collection publication date: Year: 2009
Electronic publication date: Day: 7 Month: 12 Year: 2009
Volume: 14 Issue: Suppl 4
First Page: 162 Last Page: 164
PubMed Id: 20156749
Publisher Id: 2047-783X-14-S4-162
|Dermatomyositis masquerading as pulmonary embolism|
|RM Mroz1||Email: Robmroz@wp.pl|
1Department of Chest Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland
Dermatomyositis (DM) is an idiopathic inflammatory myopathy with characteristic skin manifestations [1,2]. The prevalence of the disease is 1-10 cases per million in adults and 1-3.2 cases per million in children . In 1975, Bohan and Peter [4,5] first suggested a set of criteria to aid in the diagnosis and classification of polymyositis (PM) and DM as follows: progressive proximal symmetrical weakness, elevated levels of muscle enzymes, an abnormal finding on electromyography, an abnormal finding on muscle biopsy, and skin manifestations which are compatible with cutaneous disease (Table 1).
The study was performed according to the standards set by the Helsinki Declaration of 1975, regarding the Human Research and was approved by an institutional Ethics Committee. Informed consent was obtained from the patient described in this article.
A 61-year-old Caucasian male was admitted to Department of Chest Diseases and Tuberculosis, Medical University of Bialystok for progressive muscle weakness. The patient also developed a rash on his upper torso and back, and the extensor surfaces of all four extremities. The patient complained of generalized muscle weakness that had been present for several months but had now progressed remarkably. One and half year prior to admission, he had been admitted to the department for recurrent hemoptysis and was diagnosed with pulmonary embolism, fitting all clinical and radiological criteria. At that point he was started on enoxaparin QD. Past medical history and surgical history were unremarkable, and the patient denied the use of any tobacco or recreational drugs. He retired 6 years prior to admission. Hemoptysis stopped after first two weeks of hyperfractionated heparin treatment. He admitted to losing about 53 kilos in 18 months prior to admission, with accompanying decrease in appetite. In the interim, he developed fever, myalgia, and progressive dyspnea. He denied any previous episodes similar to this, and reported no family history of musculoskeletal disease. Physical examination revealed an ill-appearing man with an oral temperature of 38.2°C, a pulse rate of 60 beats/min, and normal blood pressure. His skin had purple confluent discoloration and swelling of the eyelids (Figure 1A), the V-shape rash with areas of hyperpigmentation of his upper torso (Figure 1B). The rash was also present on his shoulders (Figure 2A), and erythematous papules over joints (Figure 2B). Hypertrophic changes of palms and fingers (Figure 2C), were also found. Subtle dry cracles and wheezing were found on auscultation. Chest X-ray and CT scan revealed bilateral patchy consolidations and ground-glass opacities (Figure 3A and 3B). On admission, laboratory values included CPK 8229 U/l, MB fraction 219 U/l, LDH 981 U/l, and D-dimer 0.96 ng/ml. EMG was consistent with myositis. At admission, the patient was started on solumedrol 40 mg i.v, b.i.d., and then switched to prednisone 40 mg b.i.d. After two weeks of therapy, the patient's symptoms improved remarkably. His muscle strength improved and he was able to participate in physical therapy. The patient was discharged back to his facility with prednisone with an outpatient follow up.
This patient was diagnosed with dermatomyositis, fitting 4 out of the five diagnostic criteria, as outlined above: proximal muscle weakness, CPK and LDH elevations, consistent with myositis EMG, and skin manifestations [4,5]. The latter were as follows: purple confluent discoloration and swelling of the eyelids - heliotrope rush, the V-shape rash with areas of hyperpigmentation of his upper torso and shoulders, back, knees, and erythematous papules over joints - 'Gottron's sign', and hypertrophic changes of palms and fingers - 'Mechanic's hands'. The diagnosis is confirmed if a patient presents with at least 4 diagnostic criteria for PM or 3 for DM [4,5]. The fifth criterion which is confirmation of inflammatory infiltrations on muscle biopsy was not done in this case. Since our patient exhibited clinical and laboratory findings consistent with inflammatory myopathy with skin manifestations present, our diagnosis was consistent with dermatomyositis.
The cause of the disease remains unknown. Altered immune response towards viral infection is considered to play a major role [1,2]. Vascular deposits of immune complexes and complement, leading to endothelial cell injury and small vessel obstruction are most important pathogenetic factors underlying the disease . The muscles and endothelial cells are infiltrated with predominance of T CD4+ cells in DM and T CD8+ cells in PM patients . An association of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis has recently been reported [7,8]. Our patient exhibited all reported skin manifestations of DM which were: a heliotrope rash, which is a purple discoloration and swelling of the eyelids, Gottron's sign demonstrated with erythematous papules over joints, and mechanic's hands, which are: erythematous and hypertrophic skin changes of palms and fingers [1-5]. Hemoptysis, progressive dyspnea, subtle dry cracles and wheezing on auscultation, with bilateral patchy consolidations and ground-glass opacities on chest X-ray and CT scans confirmed lung interstitium disease association in our case. Hemoptysis and pulmonary embolism, lack of significant muscle weakness at the onset of the disease masqueraded underlying DM and delayed proper diagnosis. Lung involvement has been reported in minority of PM and DM cases, influencing the course and worsening prognosis in most of the cases [9,10]. An association with other connective tissue disorders (overlap syndrome) and malignancy has also been reported [9-13]. The course of the disease is usually steadily progressive, leading to profound symmetrical skeletal muscle weakness of all extremities. Patient management includes careful evaluation for underlying malignancy, physical therapy, antihistamines, sunscreen, and oral corticosteroids . Alternative therapies include corticosteroid-sparing agents, cytotoxic drugs, and more recently monoclonal antibodies with cutaneous lesions treatment [14-18]. Irresponsive disease, delay in diagnosis and the underlying malignancies worsen disease prognosis.
The authors declare that they have no competing interests.
|Krathen MS,Fiorentino D,Werth VP,DermatomyositisCurr Dir AutoimmunYear: 2008103133218460893|
|Targoff IN,Dermatomyositis and polymyositisCurr Probl DermatolYear: 1991313118010.1016/1040-0486(91)90009-S|
|Marie I,Hatron PY,Levesque H,et al. Influence of age on characteristics of polymyositis and dermatomyositis in adultsMedicine (Baltimore)Year: 19997831394710.1097/00005792-199905000-0000110352646|
|Bohan A,Peter JB,Polymyositis and dermatomyositis (first of two parts)N Engl J MedYear: 19752927344710.1056/NEJM1975021329207061090839|
|Bohan A,Peter JB,Polymyositis and dermatomyositis (second of two parts)N Engl J MedYear: 19752928403710.1056/NEJM1975022029208071089199|
|Dalakas MC,Molecular immunology and genetics of inflammatory muscle diseasesArch NeurolYear: 1998551215091210.1001/archneur.55.12.15099865793|
|Werth VP,Callen JP,Ang G,Sullivan KE,Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesisJ Invest DermatolYear: 200211936172010.1046/j.1523-1747.2002.01869.x12230503|
|Efthimiou P,Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implicationsSemin Arthritis RheumYear: 20063631687210.1016/j.semarthrit.2006.07.00316970978|
|Fujisawa T,Suda T,Nakamura Y,Enomoto N,Ide K,Toyoshima M,Uchiyama H,Tamura R,Ida M,Yagi T,Yasuda K,Genma H,Hayakawa H,Chida K,Nakamura H,Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositisJ RheumatolYear: 2005321586415630726|
|Yokoyama T,Sakamoto T,Shida N,Kinoshita M,Kunou Y,Karukaya R,Takamatsu M,Aizawa H,Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytesJ Intensive Care MedYear: 2005203160310.1177/088506660527539115888904|
|Callen JP,The value of malignancy evaluation in patients with dermatomyositisJ Am Acad DermatolYear: 198262253910.1016/S0190-9622(82)70018-07037882|
|Chow WH,Gridley G,Mellemkjaer L,McLaughlin JK,Olsen JH,Fraumeni JF Jr,Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in DenmarkCancer Causes ControlYear: 19956191310.1007/BF000516757718740|
|Whitmore SE,Rosenshein NB,Provost TT,Ovarian cancer in patients with dermatomyositisMedicine (Baltimore)Year: 1994733153608190038|
|Iorizzo LJ,Jorizzo JL,The treatment and prognosis of dermatomyositis: an updated reviewJ Am Acad DermatolYear: 20085919911210.1016/j.jaad.2008.02.04318423790|
|Majithia V,Harisdangkul V,Mycophenolate mofetil (Cell-Cept): an alternative therapy for autoimmune inflammatory myopathyRheumatology (Oxford)Year: 2005443386910.1093/rheumatology/keh49915572389|
|Nadiminti U,Arbiser JL,Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositisJ Am Acad DermatolYear: 2005522 Suppl 117915692505|
|Dalakas MC,Illa I,Dambrosia JM,Soueidan SA,Stein DP,Otero C,Dinsmore ST,McCrosky S,A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositisN Engl J Med 30Year: 19933292719932000|
|Levine TD,Rituximab in the treatment of dermatomyositis: an open-label pilot studyArthritis RheumYear: 200552601710.1002/art.2084915692974|
|1. Progressive symmetrical general muscle weakness|
|2. Typical for myositis histopathology findings|
|3. Elevated plasma level of CK and/or aldolase|
|4. EMG findings typical for primary myopathy|
|5. Typical skin findings (Gottron's sign, helitrope rash of eyelids, upper torso, arms)|
|Number of symptoms 5|
|plus characteristic skin findings|
Keywords: dermatomyositis, polymyositis, pulmonary embolism.
Conference: International Conference 'Advances in Pneumology’. Leipzig, Germany. 12-14 June 2009.
Previous Document: Onconeuronal and antineuronal antibodies in patients with neoplastic and non-neoplastic pulmonary pa...
Next Document: Increased levels of Treg cells in bronchoalveolar lavage fluid and induced sputum of patients with a...